ArticleInternational journal of clinical and experimental pathology2017
Expression of Tiam1 and Rac1 proteins in renal cell carcinoma and its clinical-pathological features.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Deciphering the oncogenic role of Rac family small GTPase 3 in hepatocellular carcinoma through multiomics integration.World journal of hepatology · 2025Article
- A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast cancer.Cell reports. Medicine · 2025Article
- Early diagnosis and prognostic potential of RAC3 in bladder tumor.International urology and nephrology · 2024Article
- Significance of RCC2, Rac1 and p53 Expression in Breast Infiltrating Ductal Carcinoma; An Immunohistochemical Study.Iranian journal of pathology · 2024Article
- The dysfunctional immune response in renal cell carcinoma correlates with changes in the metabolic landscape of ccRCC during disease progression.Cancer immunology, immunotherapy : CII · 2023Article
- A review on the role of long non-coding RNA and microRNA network in clear cell renal cell carcinoma and its tumor microenvironment.Cancer cell international · 2023Review
- Current applications of nanomaterials in urinary system tumors.Frontiers in bioengineering and biotechnology · 2023Review
- Fibulin-3 sponges Tiam1 to manipulate MMP-7 activity through β-catenin signaling in oral squamous cell carcinoma.Medical oncology (Northwood, London, England) · 2022Article
- Rac1, A Potential Target for Tumor Therapy.Frontiers in oncology · 2021Review
- Up-Regulation of Tiam1 Promotes the Radioresistance of Laryngeal Squamous Cell Carcinoma Through Activation of the JNK/ATF-2 Signaling Pathway.OncoTargets and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo explore the connections between Tiam1 and Rac1 expression in renal cell carcinoma (RCC), and its pathological type, grading, invasion and metastasis.
methodsTiam1 and Rac1 expression was measured in 60 specimens of RCC (including 42 clear cell cases, 12 papillary cases, and 6 chromophobe cases) and a 10-specimen control group using quantum dots IHC labeling, complete with clinical and pathological records, dated 2008 to 2014, were taken from the archives of the Department of Pathology, People's Hospital of Wuhan University. The expressions of Tiam1 and Rac1 proteins in specimens were measured using immunohistochemical (IHC) and quantum dots-labeling methods to examine their relationships to the clinical and pathological characteristics of RCC. The HIPAS-1000 software was used to quantitatively analyze on the results to obtain absorbance and positive area ratio (PAR) values, and SPSS 15.0 was used to perform single-factor analysis of variance and q verification. Spearman's rank correlation test is used to verify the correlation between absorbance and PAR of the two proteins.
results1. QDs IHC staining. Tiam1 and Rac1 expression is high in RCC, and low in surrounding tissues (P<0.05). 2. Expression levels of both proteins show no correlation with patient sex, age, or tumor size (P>0.05), yet correlate with the differentiation, stage, and lymphatic metastasis of tumors (P<0.05). Spearman's test shows a positive correlation between the expression levels of Tiam1 and Rac1 in RCC tissues (r=0.425, P<0.05).
conclusion1. Abnormal Tiam1 and Rac1 expression may be an early molecular event in RCC, suggesting they are carcinogens related to proto-oncogenes. 2. Tiam1 and Rac1 expression levels correlate with the differentiation, stage, and lymphatic metastasis of RCC, suggesting they play important roles in its invasion and metastasis. 3. The expression levels of Tiam1 and Rac1 are positively correlated within RCC, suggesting a synergy between the two in controlling its pathogenesis and development.
Indexed as
Identifiers
31966460PMC6965875W3007999434What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.